Top Markets
Coin of the day
TetraLogic Pharmaceuticals Corporation TetraLogic Pharmaceuticals Corporation

TetraLogic Pharmaceuticals Corporation

TLOG
Pozycja w akcjach #42528
TetraLogic Pharmaceuticals Corporation operates as a clinical-stage... TetraLogic Pharmaceuticals Corporation operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on identifying and advancing small-molecule treatments for cancer and infectious diseases. The company's development pipeline features two key clinical-stage drug candidates: birinapant and SHAPE. Birinapant, a small molecule, functions as a Second Mitochondrial Activator of Caspases (SMAC) mimetic, promoting programmed cell death, or apoptosis, in compromised cells. SHAPE, another proprietary compound, is a histone deacetylase (HDAC) inhibitor intended for topical administration to address early-stage cutaneous T-cell lymphoma. Furthermore, TetraLogic Pharmaceuticals has a research collaboration with the Walter and Eliza Hall Institute of Medical Research to explore the application of SMAC-mimetics, including birinapant, in treating infectious diseases. Founded in 2001 as Gentara Corporation, the company adopted its current name, TetraLogic Pharmaceuticals Corporation, in January 2006 and maintains its headquarters in Malvern, Pennsylvania.
Cena akcji
$0.00004
Ostatnia synchronizacja: 2026-08-11
Kapitalizacja rynkowa
$979.00
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
-60.00%
Kraj
US
Handel TetraLogic Pharmaceuticals Corporation (TLOG)

Kategoria

Historia stopy dywidendy dla TetraLogic Pharmaceuticals Corporation (TLOG)
Stopa dywidendy (TTM) dla TetraLogic Pharmaceuticals Corporation (symbol akcji: TLOG) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla TetraLogic Pharmaceuticals Corporation (TLOG) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji